Mealey's (April 26, 2021, 7:45 AM EDT) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on April 13 said substantial evidence supports a U.S. Federal Trade Commission panel decision that Impax Laboratories Inc. violated antitrust law when it accepted more than $100 million in payments to delay entry of its generic opioid drug by more than two years....